Want to see GB:DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
73.80 p
2.20 p(2.98%)
At close: 4:00 PM EDT
73.80 p
2.20 p(2.98%)
Day’s Range― - ―
52-Week Range59.15 p - 100.87 p
Previous CloseN/A
Volume588.53K
Average Volume (3M)1.82M
Market Cap
£841.32M
Enterprise Value885.85M
Total Cash (Recent Filing)£180.30M
Total Debt (Recent Filing)£393.50M
Price to Earnings (P/E)34.9
Beta1.49
Next Earnings
Nov 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield2.93%
Share Statistics
EPS (TTM)0.02
Shares Outstanding967,988,300
10 Day Avg. Volume1,078,739
30 Day Avg. Volume1,820,978
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.68
Price to Sales (P/S)0.79
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£105.00Price Target Upside42.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.05
Revenue Forecast (FY)£783.52M
Bulls Say, Bears Say
Bulls Say
Strong Cash ConversionSolid free cash flow and close alignment with operating cash flow indicate the business converts accounting earnings into liquidity. This supports investment, debt service and shareholder returns, although cash generation has shown some year-to-year volatility.
Improving LeverageThe sustained reduction in leverage improves financial flexibility and lowers balance-sheet risk relative to prior years. Stable equity and declining debt provide greater resilience as management works through slower sales and uneven consumer demand.
Operating Profit RecoveryThe rebound in operating profitability suggests that cost control, pricing or operating execution can partially restore earnings power after the 2025 trough. If sustained, improved EBIT conversion would strengthen cash generation and support reinvestment.
Bears Say
Multi-Year Revenue DeclineRepeated annual revenue contraction points to pressure on brand demand, distribution productivity or market share. A shrinking top line limits operating leverage and makes sustainable profit recovery more dependent on cost reductions rather than healthy commercial growth.
Compressed ProfitabilityMargins remain materially below historical levels, reducing the company’s buffer against promotions, input costs and foreign-exchange effects. The 2026 recovery is encouraging, but earnings durability remains unproven while gross and net margins stay depressed.
Elevated Balance-Sheet RiskAlthough leverage is improving, debt still exceeds equity, which is not a conservative structure for a consumer brand facing declining sales. Interest and refinancing needs could constrain investment or shareholder distributions if operating performance weakens again.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest share price was 59.15 p and its highest was 100.87 p in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is £841.32M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is Nov 19, 2026 which is in 93 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on May 19, 2026. The company reported 0.042 p earnings per share for the quarter, missing the consensus estimate of 0.044 p by -0.002 p.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc pays a Semiannually dividend of 1.7 p which represents an annual dividend yield of 2.93%. See more information on Dr. Martens Plc dividends here
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is <0.01.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,988,300 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of 0.042 p in its last earnings report, missing expectations of 0.044 p. Following the earnings report the stock price went up 3.266%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in GB:DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£105.00 (42.28% Upside)
£105.00 (42.28% Upside)
Insider Transactions
Bought Shares
Worth £85.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.81%
12-Months-Change
Fundamentals
Return on Equity
2.93%
Trailing 12-Months
Asset Growth
-1.40%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
DOCS Stock 12 Month Forecast
Average Price Target
105.00 p
▲(42.28% Upside)